JP4944360B2 - 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用 - Google Patents

鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用 Download PDF

Info

Publication number
JP4944360B2
JP4944360B2 JP2003501483A JP2003501483A JP4944360B2 JP 4944360 B2 JP4944360 B2 JP 4944360B2 JP 2003501483 A JP2003501483 A JP 2003501483A JP 2003501483 A JP2003501483 A JP 2003501483A JP 4944360 B2 JP4944360 B2 JP 4944360B2
Authority
JP
Japan
Prior art keywords
hepcidin
iron
mice
usf2
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003501483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004536077A (ja
JP2004536077A5 (OSRAM
Inventor
ニコラ，ガエル
ヴァウロン，ソフィー
カーン，アクセル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27224392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4944360(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP01401537A external-priority patent/EP1262187A1/en
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of JP2004536077A publication Critical patent/JP2004536077A/ja
Publication of JP2004536077A5 publication Critical patent/JP2004536077A5/ja
Application granted granted Critical
Publication of JP4944360B2 publication Critical patent/JP4944360B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/90—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving iron binding capacity of blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
JP2003501483A 2001-05-25 2002-05-24 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用 Expired - Fee Related JP4944360B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP01401377 2001-05-25
EP01401377.5 2001-05-25
EP01401537.4 2001-06-14
EP01401537A EP1262187A1 (en) 2001-05-25 2001-06-14 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
EP02290795.0 2002-03-29
EP02290795 2002-03-29
PCT/EP2002/006924 WO2002098444A2 (en) 2001-05-25 2002-05-24 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009006614A Division JP5717319B2 (ja) 2001-05-25 2009-01-15 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2011263858A Division JP2012111755A (ja) 2001-05-25 2011-12-01 鉄ホメオスタシスの調節剤としてのヘプシジンの使用

Publications (3)

Publication Number Publication Date
JP2004536077A JP2004536077A (ja) 2004-12-02
JP2004536077A5 JP2004536077A5 (OSRAM) 2012-01-26
JP4944360B2 true JP4944360B2 (ja) 2012-05-30

Family

ID=27224392

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003501483A Expired - Fee Related JP4944360B2 (ja) 2001-05-25 2002-05-24 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2009006614A Expired - Lifetime JP5717319B2 (ja) 2001-05-25 2009-01-15 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2011263858A Pending JP2012111755A (ja) 2001-05-25 2011-12-01 鉄ホメオスタシスの調節剤としてのヘプシジンの使用
JP2014090333A Expired - Lifetime JP5847231B2 (ja) 2001-05-25 2014-04-24 鉄ホメオスタシスの調節剤としてのヘプシジンの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009006614A Expired - Lifetime JP5717319B2 (ja) 2001-05-25 2009-01-15 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2011263858A Pending JP2012111755A (ja) 2001-05-25 2011-12-01 鉄ホメオスタシスの調節剤としてのヘプシジンの使用
JP2014090333A Expired - Lifetime JP5847231B2 (ja) 2001-05-25 2014-04-24 鉄ホメオスタシスの調節剤としてのヘプシジンの使用

Country Status (12)

Country Link
US (4) US7169758B2 (OSRAM)
EP (2) EP2186524B1 (OSRAM)
JP (4) JP4944360B2 (OSRAM)
CN (2) CN1612746B (OSRAM)
AT (1) ATE427114T1 (OSRAM)
AU (1) AU2002321105A1 (OSRAM)
CA (1) CA2448382C (OSRAM)
CY (1) CY1120241T1 (OSRAM)
DE (1) DE60231804D1 (OSRAM)
ES (2) ES2693050T3 (OSRAM)
TR (1) TR201806761T4 (OSRAM)
WO (1) WO2002098444A2 (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60231804D1 (de) 2001-05-25 2009-05-14 Inst Nat Sante Rech Med Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
EP1578254B1 (en) 2002-11-19 2013-03-06 DRG International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US7411048B2 (en) 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
DE10349124A1 (de) 2003-10-22 2005-05-19 Roche Diagnostics Gmbh Differenzialdiagnostik mit Hepcidin
US20060063208A1 (en) 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
KR100679100B1 (ko) * 2004-10-29 2007-02-06 엘지.필립스 엘시디 주식회사 수평 전계 인가형 액정 표시 패널 및 그 제조방법
US7968091B2 (en) 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
EP2275543A3 (en) * 2006-04-12 2011-03-09 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
WO2008011158A2 (en) * 2006-07-21 2008-01-24 Amgen Inc. Method of detecting and/ or measuring hepcidin in a sample
AU2007299629C1 (en) * 2006-09-21 2012-05-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the HAMP gene
US20110053268A1 (en) * 2006-10-17 2011-03-03 Naohisa Tomosugi Method for diagnosis of abnormal iron metabolism using active hepcidin as indicator
JP2010517529A (ja) * 2007-02-02 2010-05-27 アムジエン・インコーポレーテツド ヘプシジン及びヘプシジン抗体
US8895002B2 (en) 2007-04-09 2014-11-25 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
US8187827B2 (en) 2007-05-31 2012-05-29 Naohisa Tomosugi Diagnostic methods for acute ischemic disease using activated hepcidin as an indicator
ES2385772T3 (es) 2007-10-02 2012-07-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos específicos para la hepcidina humana
WO2009055078A2 (en) 2007-10-26 2009-04-30 University Of Utah Research Foundation Identification of the hepcidin binding site on ferroportin
CL2008003190A1 (es) 2007-11-02 2009-09-04 Lilly Co Eli Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica.
CA2722600C (en) 2008-05-01 2014-01-21 Amgen Inc. Anti-hepcidin antibodies and methods of use
PT2328931E (pt) * 2008-08-06 2013-11-07 Lilly Co Eli Anticorpos selectivos anti-hepcidina-25 e utilizações dos mesmos
US20100068737A1 (en) * 2008-09-16 2010-03-18 University Of Tennessee Research Foundation Enzyme-linked Immunosorbent Assay (ELISA) for Canine Hepcidin
US8318167B2 (en) * 2008-11-13 2012-11-27 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation of BMP-6
US8999935B2 (en) * 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
DE102009034150A1 (de) * 2009-07-20 2011-01-27 Fresenius Medical Care Deutschland Gmbh Adsorbens zur Adsorption von Hepcidin
EP2467361A1 (de) 2009-08-20 2012-06-27 Vifor (International) Ag Neue chinolin-hepcidin-antagonisten
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
BR112012005119A2 (pt) 2009-09-07 2016-11-22 Vifor Int Ag novos antagonistas de hepcidina etanodiaminas
TW201111379A (en) 2009-09-09 2011-04-01 Vifor Int Ag Novel thiazole-and oxazole-hepcidine-antagonists
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
EP2723861A4 (en) 2011-06-21 2014-12-10 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION
US9518901B2 (en) * 2011-06-29 2016-12-13 Kabushiki Kaisha Dnaform Pretreatment method of biological sample, detection method of RNA, and pretreatment kit
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
BR112015022123B1 (pt) 2013-03-15 2022-08-09 Intrinsic Lifesciences, Llc Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit
WO2014147246A1 (en) 2013-03-21 2014-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
WO2016057242A1 (en) * 2014-10-10 2016-04-14 The Board Of Regents Of The University Of Texas System HIF-2α INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS
BR112018013833A2 (pt) * 2016-01-08 2018-12-11 La Jolla Pharmaceutical Company métodos de administração de hepcidina
WO2018165186A1 (en) * 2017-03-07 2018-09-13 Intrinsic Lifesciences Llc Assessment of chronic iron deficiency
WO2019165252A1 (en) * 2018-02-23 2019-08-29 La Jolla Pharmaceutical Company Compositions comprising hepcidin and methods of use thereof
US12011489B2 (en) 2022-03-30 2024-06-18 Christopher Key Compositions and methods for treating inflammatory disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766207B1 (fr) * 1997-07-11 2000-12-08 Rhone Poulenc Agrochimie Gene chimere codant pour la drosomycine, vecteur le contenant pour la transformation des cellules vegetales et plantes transformees obtenues resistantes aux maladies
FR2770853B1 (fr) * 1997-11-07 1999-12-31 Rhone Poulenc Agrochimie Gene codant pour la thanatine, vecteur le contenant et plantes transformees obtenues resistantes aux maladies
US7232889B2 (en) * 1999-03-08 2007-06-19 Genentech, Inc. PRO300 antibodies
WO2000056879A1 (en) * 1999-03-22 2000-09-28 Universität Zürich TRANSFORMING GROWTH FACTOR (TFG) β SUPERFAMILY ANTAGONISTS
DE60231804D1 (de) * 2001-05-25 2009-05-14 Inst Nat Sante Rech Med Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
EP1578254B1 (en) † 2002-11-19 2013-03-06 DRG International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US7411048B2 (en) * 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
US8017737B2 (en) * 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US7968091B2 (en) * 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
CA2960817A1 (en) * 2006-09-16 2008-03-20 Soy Labs Llc Products and methods using soy 2s albumin
JP2010517529A (ja) † 2007-02-02 2010-05-27 アムジエン・インコーポレーテツド ヘプシジン及びヘプシジン抗体
ES2385772T3 (es) † 2007-10-02 2012-07-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos específicos para la hepcidina humana
WO2009097461A1 (en) 2008-01-29 2009-08-06 Neoguide Systems Inc. Apparatus and methods for automatically controlling an endoscope
WO2010065815A2 (en) † 2008-12-05 2010-06-10 The Regents Of The University Of California Mini-hepcidin peptides and methods of using thereof
AU2012327226C1 (en) 2011-12-09 2017-03-02 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof
CN106456703A (zh) 2014-04-07 2017-02-22 摩坚瑟生物技术股份有限公司 铁调素模拟肽及其用途
JP2017523959A (ja) 2014-06-27 2017-08-24 プロタゴニスト セラピューティクス， インコーポレイテッド ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用

Also Published As

Publication number Publication date
ATE427114T1 (de) 2009-04-15
EP1392345B1 (en) 2009-04-01
ES2326469T3 (es) 2009-10-13
JP2004536077A (ja) 2004-12-02
CN1612746B (zh) 2010-09-22
JP2014210775A (ja) 2014-11-13
US20070124825A1 (en) 2007-05-31
US10004784B2 (en) 2018-06-26
EP1392345A2 (en) 2004-03-03
EP1392345B2 (en) 2018-02-28
WO2002098444A3 (en) 2003-05-01
JP2012111755A (ja) 2012-06-14
CA2448382C (en) 2013-02-19
CA2448382A1 (en) 2002-12-12
CN101884780A (zh) 2010-11-17
US9234903B2 (en) 2016-01-12
ES2326469T5 (es) 2018-05-28
EP2186524B1 (en) 2018-02-21
CY1120241T1 (el) 2019-07-10
TR201806761T4 (en) 2018-06-21
US20050037971A1 (en) 2005-02-17
JP2009143938A (ja) 2009-07-02
US7169758B2 (en) 2007-01-30
US20160166649A1 (en) 2016-06-16
WO2002098444A2 (en) 2002-12-12
US9782453B2 (en) 2017-10-10
US20170340710A1 (en) 2017-11-30
ES2693050T3 (es) 2018-12-07
DE60231804D1 (de) 2009-05-14
CN101884780B (zh) 2018-09-21
JP5717319B2 (ja) 2015-05-13
AU2002321105A1 (en) 2002-12-16
EP2186524A1 (en) 2010-05-19
JP5847231B2 (ja) 2016-01-20
CN1612746A (zh) 2005-05-04

Similar Documents

Publication Publication Date Title
JP5847231B2 (ja) 鉄ホメオスタシスの調節剤としてのヘプシジンの使用
Jiang et al. Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1
Courselaud et al. C/EBPα regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism: cross-talk between C/EBP pathway and iron metabolism
Nishi et al. Cytoglobin, a novel member of the globin family, protects kidney fibroblasts against oxidative stress under ischemic conditions
Parry et al. Mouse embryogenesis requires the tissue factor extracellular domain but not the cytoplasmic domain
JP2007525952A (ja) Ｓ−ニトロソグルタチオンレダクターゼを調節するための組成物および方法
US20050031605A1 (en) Compositions and methods of treating diabetes
EP1262187A1 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
DE DK et al. DE LA RECHERCHE MEDICALE (INSERM)
Yesiltepe et al. Humanized TfR1 and transferrin gene-replacement rats for in vivo evaluation of BBB transport
US20070101445A1 (en) Transgenic mice carrying the HP-2 gene and uses as models for vascular diseases
JP4719862B2 (ja) カルシウム吸収促進剤
Ge Construction of adenoviruses and retroviruses of recombinant iron metabolism genes and their application in the studies on iron metabolism
CA2116012A1 (en) Transgenic non-human animal model for developing and testing therapies to treat sepsis
Toivola Keratin 20 helps maintain intermediate filament organization in digestive epithelia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050506

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081015

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090910

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091019

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20091106

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20111201

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120302

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4944360

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150309

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees